Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D6LF
|
|||
| Former ID |
DIB006819
|
|||
| Drug Name |
PD-156
|
|||
| Synonyms |
PD-503; PF-152; PF-212; PF-80; MMP-13 inhibitors (inflammation); MMP-13 inhibitors (inflammation), Pfizer
Click to Show/Hide
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Investigative | [1], [2] | |
| Company |
Pfizer Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-13 (MMP-13) | Target Info | Inhibitor | [1], [2] |
| NetPath Pathway | IL1 Signaling Pathway | |||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Plasminogen activating cascade | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| WikiPathways | Endochondral Ossification | |||
| Activation of Matrix Metalloproteinases | ||||
| Oncostatin M Signaling Pathway | ||||
| AGE/RAGE pathway | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. | |||
| REF 2 | Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the P... J Am Coll Cardiol. 2006 Jul 4;48(1):15-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.